OncoGenex CFO Exits

2/25/10

OncoGenex Pharmaceuticals,  the Bothell, WA-based developer of a prostate cancer drug, said today that its chief financial officer, Stephen Anderson, left the company yesterday. OncoGenex (NASDAQ: OGXI) is searching for a replacement, who is “suited for the next stage of company growth, with deep ties in the biopharma investment community and experience transitioning a pharmaceutical company from R&D stage to commercial development,” the company said in a statement. OncoGenex stock closed yesterday at $16.72, down 43 percent since December 21, when it announced a partnership with Teva Pharmaceutical to co-develop its lead drug candidate, OGX-011.

By posting a comment, you agree to our terms and conditions.